Drug Trial Radar · NCT02482753
Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jan 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
365
Actual
Start
Jul 2015
Primary completion
Mar 2018
Study completion Feb 2021
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study was to evaluate the efficacy and safety of Chidamide in combination with exemestane in postmenopausal patients with hormone-receptor positive advanced breast cancer.
Conditions
- Breast Cancer
Interventions
ChidamideDrug
30 mg, administered orally twice per week (BIW)
exemestaneDrug
25 mg, PO daily
placeboDrug
Administered orally twice per week (BIW)
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survival (PFS), double-blinded periodTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years
- pharmacokinetic profiles of Chidamide, open-label periodTime frame: 0,1,2,4,8,12,24,48,72 hours after the first dose of Chidamide on day 2 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage
- pharmacokinetic profiles of exemestane, open-label periodTime frame: 0,1,2,4,8,12,24 hours after the first dose of exemestane on day 1 at induced stage (4 days in total); 0,1,2,4,8,12,24,48,72 hours post-dose on day 1 of cycle 1 at combination treatment stage
- acetylation level of histone H3, open-label periodTime frame: pre-dose of Chidamide on day 2 at induced stage (4 days in total); pre-dose of Chidamide on day 1 of cycle 2 at combination treatment stage
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
The 307th Hospital of Chinese people's Liberation Army
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Cangzhou Central Hospital
Cangzhou, Hebei, China
Tumor Hospital of Hebei Province
Shijiazhuang, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Hunan Cancer Hospital
Changsha, Hunan, China
Zhejiang Cancer Hospital
Hangzhou, Jiangsu, China
Jiangsu Cancer Hospital
Nanjing, Jiangsu, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The Third Hospital of Nanchang
Nanchang, Jiangxi, China
Jilin Cancer Hospital
Changchun, Jilin, China
The First Hospital of Jilin University
Changchun, Jilin, China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
Jinan Central Hospital
Jinan, Shandong, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Fudan University ZhongShan Hospital
Shanghai, Shanghai Municipality, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.